 "reddy, dr reddy's")
Dr Reddy’s Laboratories was trading lower for the fourth straight trading day, down 3.4% at Rs 2,233 on BSE after the company reported 29% year on year (YoY) decline in its consolidated net profit at Rs 3,344 million in December 2017 quarter (Q3FY18).
The net profit was impacted by a Rs 930 million charge on revaluation of deferred tax assets post the changing tax laws in the US.
Analysts on an average had expected profit of Rs 3,380 million for the quarter.
The net profit was impacted by a Rs 930 million charge on revaluation of deferred tax assets post the changing tax laws in the US.
Analysts on an average had expected profit of Rs 3,380 million for the quarter.
Revenues grew 3% at Rs 38,060 million against Rs 37,065 million in the corresponding quarter of
